Atrial Fibrillation (also called AFib) is an irregular heart beat that impacts millions of people in the United States, according to the American Heart Association.

Normally, the heart contracts and then relaxes in a regular rhythm. For patients with AFib, the heart beats abnormally which may cause symptoms including shortness of breath, fatigue, dizziness and chest pain. Risks associated with AFib include stroke and heart failure, according to the National Institutes of Health.

CONVERGE is a clinical trial to establish the safety and efficacy of the Convergent Procedure for persistent AFib.

Key facts about the Convergent Procedure:

Hybrid approach performed by board-certified cardiologists and cardiac surgeons working as a team.

Minimally-invasive surgery

• Typically performed in a cardiac catheter lab.

• The goal of the Convergent Procedure is for patients to be free from AFib without any medication.

Compensation may be provided to patients who qualify for the CONVERGE trial and there are no study-related costs.

DO I QUALIFY?Take a 60-second survey

Have Questions? Call (844) 202-8199 between
the hours of 8am to 8pm, Monday through Friday.